Wide Ranks

ASMB

Assembly Biosciences, Inc.

16.83

Top Statistics
Market Cap 106 M Forward PE -2.10 Revenue Growth 0.00 %
Current Ratio 2.74 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins -212.33 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -0.0710 Enterprise / Revenue 0.1660 Price To Sales Trailing12 Months 4.98
Profitability
Profit Margins -212.33 % Operating Margins -143.01 %
Balance Sheet
Total Cash 109 M Total Cash Per Share 17.21 Total Debt 1 M
Total Debt To Equity 5.03 Current Ratio 2.74 Book Value Per Share 7.50
All Measures
Short Ratio 41.00 % Message Board Id finmb_99715344 Shares Short Prior Month 23101
Return On Equity -1.02 City South San Francisco Uuid 5ccb3150-4a3d-31e5-b37e-d19135911383
Previous Close 15.20 First Trade Date Epoch Utc 1 B Book Value 7.50
Beta 0.5880 Total Debt 1 M Volume 89327
Price To Book 2.25 Last Split Date 1 B Fifty Two Week Low 8.40
Total Cash Per Share 17.21 Total Revenue 21 M Shares Short Previous Month Date 1 B
Target Median Price 35.50 Audit Risk 3 Max Age 86400
Sand P52 Week Change 0.3133 Operating Margins -143.01 % Target Mean Price 35.50
Net Income To Common -45611000 Short Percent Of Float 0.0038 Implied Shares Outstanding 6 M
Trailing Peg Ratio None Last Fiscal Year End 1 B Average Daily Volume10 Day 37710
Average Volume10days 37710 Total Cash 109 M Next Fiscal Year End 1 B
Revenue Per Share 4.12 Held Percent Insiders 0.3162 Ebitda Margins -234.01 %
Trailing PE 0.0000 Date Short Interest 1 B Most Recent Quarter 1 B
Share Holder Rights Risk 2 Regular Market Previous Close 15.20 Target Low Price 35.00
Gmt Off Set Milliseconds -18000000 Fifty Day Average 16.35 Open 15.35
Free Cashflow 5 M State CA Dividend Yield 0.00 %
Return On Assets -0.3472 Time Zone Short Name EST Board Risk 4
Trailing Eps -6.89 Day Low 15.35 Address1 Two Tower Place
Shares Outstanding 6 M Compensation Risk 6 Price Hint 2
Target High Price 36.00 Website https://www.assemblybio.com 52 Week Change 1.00
Average Volume 31679 Forward Eps -6.94 Recommendation Key none
Compensation As Of Epoch Date 1 B Quick Ratio 265.60 % Last Split Factor 1:12
Regular Market Day High 16.83 Is_sp_500 False Profit Margins -212.33 %
Debt To Equity 5.03 Fifty Two Week High 19.93 Day High 16.83
Shares Short 16423 Regular Market Open 15.35 Industry Key biotechnology
Earnings Growth 0.00 % Enterprise To Revenue 0.1660 Revenue Growth 0.00 %
Shares Percent Shares Out 0.0026 Operating Cashflow 24 M Currency USD
Time Zone Full Name America/New_York Market Cap 106 M Is_nasdaq_100 False
Zip 94080 Quote Type EQUITY Industry Biotechnology
Long Name Assembly Biosciences, Inc. Overall Risk 3 Regular Market Day Low 15.35
Held Percent Institutions 0.1879 Current Price 16.83 Address2 7th Floor
Enterprise To Ebitda -0.0710 Financial Currency USD Current Ratio 2.74
Gross Margins -132.62 % Industry Disp Biotechnology Number Of Analyst Opinions 2
Country United States Float Shares 3 M Two Hundred Day Average 14.73
Governance Epoch Date 1 B Enterprise Value 3 M Price To Sales Trailing12 Months 4.98
Forward PE -2.10 Regular Market Volume 89327 Ebitda -50267000
Exchange NMS
Go to Yahoo Finance Go to Seeking Alpha 
Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases.

It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial.

The company also develops ABI-4334, a next-generation capsid assembly modulator, which is in Phase 1b clinical trial for the treatment of hepatitis B virus (HBV).

In addition, it develops an oral non-nucleoside polymerase inhibitor targeting transplant-related herpesviruses; and a small molecule interferon-a receptor agonist targeting HBV and HDV.

The company has collaboration agreements with Gilead Sciences, Inc. and BeiGene, Ltd.

The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014.

Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.